| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
O'Donnell Niall serves as a Director at OKUR and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 5 buys and 3 sells. Those positions are worth an estimated $53.6M at current prices.
Historically, O'Donnell Niall's trades have earned a below-average insider score of 40/100 across 6 rated trades. Over a 12-month horizon, 16.7% of those trades were profitable, with an average 12-month return of -35.3%.
The biggest single holding is MIRM (~$31.9M) as Director.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2023 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 125,000 | $8.00 | $1,000,000.00 | +6.1% | -28.4% | -81.4% | |
| Feb 16, 2023 | SPRB Spruce Biosciences, Inc. | Director | Buy | 630,400 | $3.17 | $1,998,368.00 | +90.6% | -8.4% | +100.0% | |
| Nov 15, 2022 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sell | 300,000 | $19.86 | $5,956,855.05 | -15.6% | +17.5% | +51.6% | |
| Apr 13, 2021 | OKUR Onkure Therapeutics, Inc. | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | +10.7% | -26.7% | -77.4% | |
| Oct 14, 2020 | SPRB Spruce Biosciences, Inc. | Director | Buy | 250,000 | $15.00 | $3,750,000.00 | +56.1% | - | - | |
| Jul 22, 2019 | MIRM Mirum Pharmaceuticals, Inc. | Director | Buy | 300,000 | $15.00 | $4,500,000.00 | +18.5% | - | - |